News & Events

  • 12 Mar 2015
  • Hetero Received generic Sofosbuvir (Gilead's Sovaldi) approval from drug controller general of India (DCGI)
  • Hetero.  A leading pharmaceutical company based in Hyderabad, India today announced that it has received approval for generic Sofosbuvir Tablets, 400 mg, from Drug Controller General of India.


    Hetero will launch Sofosbuvir under its brand Sofovir in India. Hetero will price its generic medicine at Rs. 19,900 for a bottle of 28 tablets and will launch the medicine this month in India and other countries soon. Hetero has also tied up with various other License holders to distribute the generic Sofobuvir in India.


    Sofosbuvir 400 mg tablets,  a once-daily oral dose is being used for the treatment of chronic hepatitis C infection across the world. This will herald the beginning of a new era in Hepatitic-C treatment.

    Hetero has a non-exclusive License Agreement with Gilead Sciences, Ireland to manufacture and sell generic versions of its chronic hepatitis C medicines in 91 developing countries.


    “Hepatitis C is a growing public health concern, particularly in developing countries such as India and Hetero is committed to bringing affordable sofosbuvir to India” said Vamsi Krishna, Director-Hetero.